UNSPSC 51333900: Antipsychotic quinolines

Antipsychotic drugs made from compounds consisting of a catabolite of tryptophan.

UNSPSC 51333900 Antipsychotic quinolines is a Class code with minimal alignment to the recent state and local contract opportunities posted under it. The code nominally covers a specific class of psychiatric medications, but the three most recent opportunities solicited under this UNSPSC—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's request for information on direct-to-manufacturer prescription programs, and MMCAP's generic multi-source pharmaceuticals and OTC products—do not reflect antipsychotic quinoline purchasing. The opportunities instead span emergency medical supplies, pharmacy benefit program administration, and broad-spectrum generic pharmaceutical distribution. State and local issuers in the recent block include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS), and cooperative purchasing alliances serving multi-state public entities (MMCAP, administered by Minnesota Department of Administration). The code shows little decision-relevant recent activity for firms specializing in antipsychotic quinolines specifically.

Activity spans Florida, Texas, and Minnesota through the MMCAP multi-state cooperative. Seminole County issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023, with posting on June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year term with a one-year renewal option and requires E-Verify compliance and specific insurance coverage. Texas HHS issued an RFI (HHS0017013, posted April 3, 2026, same-day response deadline) to gather vendor capabilities on direct-to-manufacturer prescription programs for therapeutic pharmacy initiatives, framed as preliminary market research preceding a formal RFP. MMCAP posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The code's mismatch with recent solicitation content suggests tagging error or that antipsychotic quinoline procurement by state and local entities does not currently generate posted opportunities in the dataset.